pavmed is a groundbreaking medical device company bringing innovative medical technologies from concept to commercialization with unprecedented speed and efficiency. led by three accomplished medical device entrepreneurs and organized to conceive, develop and commercialize a diversified pipeline of innovative products we believe address unmet clinical needs, our goal is to enhance and accelerate value creation by employing a business model focused on capital and time efficiency.
Company profile
Ticker
PAVM
Exchange
Website
CEO
Lishan Aklog
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
PAXmed Inc.
SEC CIK
Corporate docs
Subsidiaries
(PAVmed Inc. • Lucid Diagnostics Inc. • LucidDx Labs Inc. • Veris Health Inc. • Oncodisc Inc • CapNostics LLC ...
PAVM stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
25 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Mar 24
8-K
Completion of Acquisition or Disposition of Assets
15 Feb 24
8-K
Other Events
9 Feb 24
S-8
Registration of securities for employees
6 Feb 24
S-8
Registration of securities for employees
6 Feb 24
8-K
Other Events
30 Jan 24
8-K
Other Events
8 Jan 24
Transcripts
PAVM
Earnings call transcript
2023 Q4
27 Mar 24
PAVM
Earnings call transcript
2023 Q3
15 Nov 23
PAVM
Earnings call transcript
2023 Q2
16 Aug 23
PAVM
Earnings call transcript
2023 Q1
17 May 23
PAVM
Earnings call transcript
2022 Q4
15 Mar 23
PAVM
Earnings call transcript
2022 Q3
16 Nov 22
PAVM
Earnings call transcript
2022 Q2
17 Aug 22
PAVM
Earnings call transcript
2022 Q1
13 May 22
PAVM
Earnings call transcript
2021 Q4
29 Mar 22
PAVM
Earnings call transcript
2021 Q3
17 Nov 21
Latest ownership filings
4
Timothy E Baxter
23 Feb 24
4
Debra White
23 Feb 24
4
Ronald M Sparks
23 Feb 24
4
Joan B Harvey
23 Feb 24
4
Michael J Glennon
23 Feb 24
4
James L Cox
23 Feb 24
4
Lucid Diagnostics Inc.
20 Feb 24
SC 13D/A
Lucid Diagnostics Inc.
20 Feb 24
SC 13G
Ayrton Capital LLC
14 Feb 24
SC 13D/A
Lucid Diagnostics Inc.
2 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.41 mm | 26.41 mm | 26.41 mm | 26.41 mm | 26.41 mm | 26.41 mm |
Cash burn (monthly) | 3.59 mm | 2.53 mm | 7.25 mm | 7.20 mm | 3.70 mm | 4.75 mm |
Cash used (since last report) | 21.45 mm | 15.15 mm | 43.39 mm | 43.10 mm | 22.12 mm | 28.42 mm |
Cash remaining | 4.95 mm | 11.26 mm | -16.98 mm | -16.69 mm | 4.29 mm | -2.01 mm |
Runway (months of cash) | 1.4 | 4.4 | -2.3 | -2.3 | 1.2 | -0.4 |
Institutional ownership, Q3 2023
10.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 69 |
Opened positions | 15 |
Closed positions | 3 |
Increased positions | 12 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 3.62 bn |
Total shares | 12.49 mm |
Total puts | 0.00 |
Total calls | 126.40 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 3.81 mm | $1.12 bn |
Ayrton Capital | 2.24 mm | $661.15 mm |
BLK Blackrock | 1.12 mm | $331.06 mm |
First Manhattan | 1.00 mm | $294.60 mm |
Geode Capital Management | 826.09 k | $243.44 mm |
Valeo Financial Advisors | 322.27 k | $94.94 mm |
WFC Wells Fargo & Co. | 301.60 k | $88.85 mm |
STT State Street | 281.39 k | $82.90 mm |
XML Financial | 154.99 k | $45.66 mm |
Levin Capital Strategies | 149.75 k | $44.12 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Jan 24 | PAVmed | Common Stock | Other | Acquire J | No | No | 1.4033 | 3,331,771 | 4.68 mm | 34,634,191 |
30 Jan 23 | Joan B Harvey | Employee stock option Common stock | Grant | Acquire A | No | No | 0 | 450,000 | 0.00 | 450,000 |
30 Jan 23 | Timothy E Baxter | Employee stock option Common stock | Grant | Acquire A | No | No | 0 | 450,000 | 0.00 | 450,000 |
30 Jan 23 | Glennon Michael J | Employee stock option Common stock | Grant | Acquire A | No | No | 0 | 450,000 | 0.00 | 450,000 |
30 Jan 23 | Debra White | Employee stock option Common stock | Grant | Acquire A | No | No | 0 | 450,000 | 0.00 | 450,000 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
29 Mar 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
28 Mar 24
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
27 Mar 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
27 Mar 24
Earnings Scheduled For March 26, 2024
26 Mar 24
Press releases
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
26 Mar 24
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
25 Mar 24
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
21 Mar 24
PAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX
21 Mar 24
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
20 Mar 24